CYCCPライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (29 4月 2024 @ 22:55):

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases...

Stats
本日の出来高	696.00
平均出来高	1 501.00
時価総額	1.82M
EPS	$0 ( 2023-09-29 )
Last Dividend	$0.150 ( 2024-01-19 )
Next Dividend	$0 ( N/A )
P/E	-4.08
ATR14	$0.379 (4.53%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-21	Mcbarron Paul	Buy	1 886	Common Stock
2023-12-21	Mcbarron Paul	Buy	1 886	Warrants (right to buy)
2023-12-21	Rombotis Spiro George	Buy	6 070	Common Stock
2023-12-21	Rombotis Spiro George	Buy	6 070	Warrants (right to buy)
2023-06-30	Rombotis Spiro George	Buy	110 000	Stock Option (right to buy)

INSIDER POWER
100.00
Last 94 transactions
Buy: 4 220 559 \| Sell: 12

Cyclacel Pharmaceuticals 相関

10 最も正の相関
ALSA	0.919
LCAA	0.913
XFIN	0.908
ALXN	0.905
IQ	0.905
PLYA	0.904
JUGG	0.902
IVCP	0.901
VPCB	0.901
TIOAU	0.9

10 最も負の相関
SIDU	-0.91
MTP	-0.902
JAGX	-0.902
EVLO	-0.892
ENNV	-0.89
PROC	-0.889
DBGI	-0.885
LGMK	-0.885
TRMK	-0.883
SLNG	-0.879

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Cyclacel Pharmaceuticals 財務諸表

Annual	2023
収益:	$420 000
総利益:	$389 000 (92.62 %)
EPS:	$-26.51

FY	2023
収益:	$420 000
総利益:	$389 000 (92.62 %)
EPS:	$-26.51

FY	2022
収益:	$0
総利益:	$-32 000.00 (0.00 %)
EPS:	$-32.23

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-9.93

Financial Reports:

No articles found.

Cyclacel Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.150 (N/A)	$0.150 (N/A)	$0.150 (N/A)	$0.150 (N/A)	$0.150 (N/A)	$0.150 (N/A)	$0.150 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Cyclacel Pharmaceuticals Dividend Information - Dividend Knight

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 5.00 - Potential for dividend initiation, but uncertain (0.00%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.150	2006-01-18
Last Dividend	$0.150	2024-01-19
Next Dividend	$0	N/A
Payout Date	2024-02-01
Next Payout Date	N/A
# dividends	59	--
Total Paid Out	$8.85	--
Avg. Dividend % Per Year	5.36%	--
Score	4.44	--
Div. Sustainability Score	0
Div.Growth Potential Score	5.00
Div. Directional Score	0.683	--

Next Divdend (Est)
(2024-05-06)

$0.153 Estimate 59.78 %

Dividend Stability

0.96 Excellent

Dividend Score

4.44

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2006	$0.600	14.50%
2007	$0.600	11.20%
2008	$0.600	12.60%
2009	$0.150	7.89%
2010	$0	0.00%
2011	$0.300	7.71%
2012	$0	0.00%
2013	$0.600	6.67%
2014	$0.750	8.13%
2015	$0.450	6.96%
2016	$0.600	15.30%
2017	$0.600	9.68%
2018	$0.600	9.16%
2019	$0.600	9.60%
2020	$0.450	9.00%
2021	$0.600	8.53%
2022	$0.600	9.68%
2023	$0.600	5.19%
2024	$0.150	0.91%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-53.86	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-2.57	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-3.10	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	-0.00889	-1.000	-0.0889	0.0889	[0 - 1]
currentRatioTTM	0.912	0.800	-0.439	-0.351	[1 - 3]
quickRatioTTM	0.773	0.800	-0.157	-0.126	[0.8 - 2.5]
cashRatioTTM	0.414	1.500	8.81	10.00	[0.2 - 2]
debtRatioTTM	0.00420	-1.500	9.93	-10.00	[0 - 0.6]
interestCoverageTTM	239.38	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	-18.87	2.00	-6.29	-10.00	[0 - 30]
freeCashFlowPerShareTTM	-18.87	2.00	-9.44	-10.00	[0 - 20]
debtEquityRatioTTM	0.0610	-1.500	9.76	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.0580	1.000	-2.37	-2.37	[0.2 - 0.8]
operatingProfitMarginTTM	-61.55	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-435.46	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.0477	0.800	-3.02	-2.41	[0.5 - 2]
Total Score				-3.63

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-0.0570	1.000	-0.107	0	[1 - 100]
returnOnEquityTTM	-3.10	2.50	-10.00	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-18.87	2.00	-6.29	-10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-18.87	2.00	-6.29	-10.00	[0 - 30]
payoutRatioTTM	-0.00889	1.500	-0.0889	0.0889	[0 - 1]
pegRatioTTM	-0.00201	1.500	-3.35	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-38.36	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-4.53

Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.